In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial.
Journal
Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
23
03
2020
revised:
31
05
2020
accepted:
11
06
2020
pubmed:
28
6
2020
medline:
19
8
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
Obstructive sleep apnea (OSA) is associated with increased mortality and readmissions in patients with heart failure (HF). The effect of in-hospital diagnosis and treatment of OSA during decompensated HF episodes remains unknown. A single-site, randomized, controlled trial of hospitalized patients with decompensated HF (n = 150) who were diagnosed with OSA during the hospitalization was undertaken. All participants received guideline-directed therapy for HF decompensation. Participants were randomized to an intervention arm which received positive airway pressure (PAP) therapy during the hospitalization (n = 75) and a control arm (n = 75). The primary outcome was discharge left ventricular ejection fraction (LVEF). The LVEF changed in the PAP arm from 25.5 ± 10.4 at baseline to 27.3 ± 11.9 at discharge. In the control group, LVEF was 27.3 ± 11.7 at baseline and 28.8 ± 10.5 at conclusion. There was no significant effect on LVEF of in-hospital PAP compared with controls (P = .84) in the intention-to-treat analysis. The on-treatment analysis in the intervention arm showed a significant increase in LVEF in participants who used PAP for ≥3 hours per night (n = 36, 48%) compared with those who used it less (P = .01). There was a dose effect with higher hours of use associated with more improvement in LVEF. Follow-up of readmissions at 6 months after discharge revealed a >60% decrease in readmissions for patients who used PAP ≥3 h/night compared with those who used it <3 h/night (P < .02) and compared with controls (P < .04). In-hospital treatment with PAP was safe but did not significantly improve discharge LVEF in patients with decompensated HF and newly diagnosed OSA. An exploratory analysis showed that adequate use of PAP was associated with higher discharge LVEF and decreased 6 months readmissions.
Sections du résumé
BACKGROUND
BACKGROUND
Obstructive sleep apnea (OSA) is associated with increased mortality and readmissions in patients with heart failure (HF). The effect of in-hospital diagnosis and treatment of OSA during decompensated HF episodes remains unknown.
METHODS AND RESULTS
RESULTS
A single-site, randomized, controlled trial of hospitalized patients with decompensated HF (n = 150) who were diagnosed with OSA during the hospitalization was undertaken. All participants received guideline-directed therapy for HF decompensation. Participants were randomized to an intervention arm which received positive airway pressure (PAP) therapy during the hospitalization (n = 75) and a control arm (n = 75). The primary outcome was discharge left ventricular ejection fraction (LVEF). The LVEF changed in the PAP arm from 25.5 ± 10.4 at baseline to 27.3 ± 11.9 at discharge. In the control group, LVEF was 27.3 ± 11.7 at baseline and 28.8 ± 10.5 at conclusion. There was no significant effect on LVEF of in-hospital PAP compared with controls (P = .84) in the intention-to-treat analysis. The on-treatment analysis in the intervention arm showed a significant increase in LVEF in participants who used PAP for ≥3 hours per night (n = 36, 48%) compared with those who used it less (P = .01). There was a dose effect with higher hours of use associated with more improvement in LVEF. Follow-up of readmissions at 6 months after discharge revealed a >60% decrease in readmissions for patients who used PAP ≥3 h/night compared with those who used it <3 h/night (P < .02) and compared with controls (P < .04).
CONCLUSIONS
CONCLUSIONS
In-hospital treatment with PAP was safe but did not significantly improve discharge LVEF in patients with decompensated HF and newly diagnosed OSA. An exploratory analysis showed that adequate use of PAP was associated with higher discharge LVEF and decreased 6 months readmissions.
Identifiants
pubmed: 32592897
pii: S1071-9164(20)30310-9
doi: 10.1016/j.cardfail.2020.06.007
pmc: PMC7484161
mid: NIHMS1616759
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
705-712Subventions
Organisme : NHLBI NIH HHS
ID : R21 HL092480
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Références
Biom J. 2006 Dec;48(6):984-91
pubmed: 17240656
J Am Coll Cardiol. 2014 Apr 1;63(12):1123-1133
pubmed: 24491689
J Card Fail. 2013 Jun;19(6):431-44
pubmed: 23743494
Circulation. 2016 Jan 26;133(4):e38-360
pubmed: 26673558
Eur Respir J. 2018 May 10;51(5):
pubmed: 29748245
N Engl J Med. 2015 Sep 17;373(12):1095-105
pubmed: 26323938
J Am Coll Cardiol. 2017 Feb 21;69(7):841-858
pubmed: 28209226
Am J Respir Crit Care Med. 2004 Feb 1;169(3):361-6
pubmed: 14597482
Curr Treat Options Cardiovasc Med. 2018 Mar 22;20(4):33
pubmed: 29568980
Sleep Med Clin. 2017 Jun;12(2):205-219
pubmed: 28477775
Curr Cardiol Rev. 2015;11(1):53-62
pubmed: 24251454
J Card Fail. 2013 Feb;19(2):108-16
pubmed: 23384636
Eur Heart J. 2015 Jun 14;36(23):1463-9
pubmed: 25636743
Circulation. 2013 Oct 15;128(16):e240-327
pubmed: 23741058
J Card Fail. 2012 Jul;18(7):534-40
pubmed: 22748486
Eur J Heart Fail. 2007 Mar;9(3):251-7
pubmed: 17027333
J Am Coll Cardiol. 2013 Jan 29;61(4):391-403
pubmed: 23219302
Circulation. 2017 Aug 8;136(6):e137-e161
pubmed: 28455343
N Engl J Med. 2016 Sep 8;375(10):919-31
pubmed: 27571048
Eur Respir J. 2004 Sep;24(3):443-8
pubmed: 15358704
N Engl J Med. 2003 Mar 27;348(13):1233-41
pubmed: 12660387
Chest. 2009 Oct;136(4):991-997
pubmed: 19567491
Cochrane Database Syst Rev. 2013 May 31;(5):CD005351
pubmed: 23728654
J Card Fail. 2009 Nov;15(9):739-46
pubmed: 19879459
Arch Cardiovasc Dis. 2009 Mar;102(3):169-75
pubmed: 19375670
JAMA. 2017 Nov 28;318(20):2042-2043
pubmed: 29183061